Vor Biopharma has dramatically shifted strategy from oncology to autoimmune disorders, securing $175 million in private equity to support this transition. The company licensed global rights to telitacicept, a fusion protein drug approved in China for generalized myasthenia gravis, lupus, and rheumatoid arthritis, with Phase 3 studies ongoing globally. This pivot comes after significant operational downsizing earlier in 2025. Vor appointed Jean-Paul Kress, former MorphoSys leader, as new CEO to helm the transformation. The move underscores increasing interest in autoimmune therapeutics and highlights the growing role of Chinese biotech in licensing innovative drug candidates to Western companies.